bipolar%20disorder
BIPOLAR DISORDER
Bipolar I disorder is primarily defined by manic or mixed episodes that last for at least 7 days, or very severe manic symptoms needing immediate hospital care. The patient also has depressive episodes which may last for at least 2 weeks.
Bipolar II disorder is usually misdiagnosed. It is characterized by occurence of ≥1 major depressive episodes with at least 1 hypomanic episode.
Cyclothymic disorder or cyclothymia is a mild form of bipolar disorder. Patients have  episodes of hypomania alternating with mild depression that lasts for 2 years.
Rapid-cycling bipolar disorder patients have ≥4 episodes of major depression, mania, hypomania or mixed symptoms within a year.

Bipolar%20disorder Patient Education

Patient Education

General Recommendations

Patient and Family Education

  • Treatment plan needs to be discussed with both patient and family members
    • Discuss expected results, dosing strategies, side effects and drug interactions
  • They need to understand that long-term treatment is necessary
    • Education should continue throughout treatment
  • Educate patient and family about prodromal symptoms
    • Teach them to recognize early signs and symptoms of manic and depressive episodes and how to prevent
    • Patient may keep diary of events and moods over time to assist in this process
    • Teach them about destigmatization and non-discrimination
      • Specific strategies such as enhancing coping skills through improvements in self-esteem, empowerment and help-seeking behavior can help reduce stigma and can improve outcomes

Treatment Compliance

  • Encourage treatment compliance because noncompliance may lead to relapse
    • Must overcome patient’s ambivalence towards treatment
    • Patient may find mania/euphoric episode enjoyable hence fueling reluctance to medication

Manage Functional Impairment

  • Patients may suffer emotional, family, social, occupational, financial or academic problems during an episode
  • Full functional recovery rarely occurs within 12 weeks following the remission of mood symptoms
    • May need assistance in addressing the psychosocial consequences of their actions
    • Patient should be advised to withdraw from work or other responsibilities when needed
    • Major life decisions should not be done while in depressed, manic or hypomanic state

Psychosocial Stressors

  • Enhance coping strategy & problem solving skills in managing psychosocial stressors
  • Disruption in sleep cycles or social rhythm can trigger manic episodes
    • Disruption of sleep is usually the final common pathway trigerring manic episodes
    • Patient and family should be educated on the potential consequences and taught coping strategies
    • Patient may benefit from regular daily activity pattern, including eating, sleeping and physical activities along with emotional and social stimulation
  • Proper assessment, advice and treatment is required in managing patients who abuse substance/alcohol
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 18 hours ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.